Strategies for the prevention of autoimmune Type 1 diabetes

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1141-1143

  Todd, J A ^a   Knip, M ^b   Mathieu, C ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; HEMOGLOBIN A1C; HLA ANTIGEN CLASS 2; INTERFERON; INTERLEUKIN 2; PREPROINSULIN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIMARY PREVENTION; REVIEW; RISK FACTOR;

AGE OF ONSET; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; PRIMARY PREVENTION; RESEARCH DESIGN; RISK FACTORS;

EID: 80053003538     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03400.x     Document Type: Review

References (8)

1. Todd JA. Etiology of type1 diabetes. Immunity 2010; 32: 457-467.
2. Skowera A, Ellis RJ, Varela-Calvino R, Arif S, Huang GC, Van-Krinks C et al. CTLs are targeted to kill beta cells in patients with type1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118: 3390-3402.
3. Siljander HT, Simell S, Hekkala A, Lähde J, Simell T, Vähäsalo P et al. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009; 58: 2835-2842.
4. Winkler C, Lauber C, Adler K, Grallert H, Illig T, Ziegler AG, Bonifacio E. An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type1 diabetes. Diabetes 2011; 60: 685-690.
5. Bingley PJ, Gale EA. Progression to type1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 2006; 49: 881-890.
6. Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type1 diabetes. Diabetes 2005; 54: S125-S136.
7. Hagopian WA, Erlich H, Lernmark A, Rewers M, Ziegler AG, Simell O et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421000 infants. Pediatr Diabetes 2011; doi: 10.1111/j.1399-5448.2011.00774.x [Epub ahead of print].
8. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A et al. Nasal insulin to prevent type1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372: 1746-1755.